Kalayanarooj Siripen
WHO Collaborating Centre for Case Management of Dengue/DHF/DSS, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand.
J Med Assoc Thai. 2008 Oct;91 Suppl 3:S97-103.
DHF is characterized by plasma leakage and abnormal hemostasis. About 20% of DHF patients do require colloidal solution in addition to conventional crystalloid solution for the treatment. There is only one colloidal solution, 10% Dextran-40 in NSS that proved to be effective for this group of DHF patients.
To compare 10% dextran-40 in NSS with 10% Haes-steril in NSS in the management of DHF cases with severe plasma leakage for their effectiveness and impact on renal function, hemostasis, disease severity, and complications.
DHF patients admitted to Dengue Unit, QSNICH, who do not respond to conventional crystalloid solution, are randomly assigned to receive either dextran or haes-steril. Clinical and laboratory comparison are recorded and analyzed using SPSS for Window version 14.0.
There are 104 DHF patients enrolled in the study; 57 are assigned in dextran and 47 in haes-steril group. The mean ages are 8.6 +/- 3.9 years. About half of the patients in both groups require one dose of colloidal solution and 25% require 2 and 3 doses (p = 0.138). The average amount of IV fluid infused in dextran and haes-steril group are 119.4 and 129.3 ml (p = 0.227). The average drop in Hct after the bolus dose of both colloid are 7.9 and 8.5% (p = 0.381). About 80% of the patients in each group have shock (p = 0.843). The mean elevation of AST are 598 and 822 U (p = 0.548) while ALT elevation are 182 and 306 U (p = 0.265) in dextran and haes-steril group, respectively. BUN and creatinine are within normal limits and are decreased after the use of colloidal solutions. The amount of urine on day 1, 2 and 3 after the use of both colloidal solutions are not different. Coagulogram studies (PT, PTT and TT) in both groups are not different. Patients with significant bleeding and who require blood transfusions are 15.8 and 19.2% in dextran and haes-steril group (p = 0.423).The incidence of fluid overload in dextran and haes-steril group are 35.1 and 40.4% (p = 0.360). Other complications are not different between dextran and haes-steril group as follows: hypocalcaemia, hyponatremia, hypokalemia and acidosis. The overall severity and complications in both groups of patients are much higher than in DHF patients who respond to conventional crystalloid solution. No allergic reaction was found after the use of both colloidal solutions.
10% Haes-steril is as effective as 10% dextran-40 in the treatment of DHF patients who have severe plasma leakage. There are no differences in DHF disease severity and complications in both groups but the disease severity and complications, especially fluid overload are observed to be more comparative with admitted DHF patients. Both colloidal solutions are safe in DHF patients with no allergic reaction observed and no interference in renal functions and hemostasis.
登革出血热(DHF)的特征为血浆渗漏和止血异常。约20%的DHF患者在使用传统晶体溶液治疗的基础上还需要胶体溶液。仅有1种胶体溶液,即生理盐水中的10%右旋糖酐-40,被证明对这类DHF患者有效。
比较生理盐水中的10%右旋糖酐-40与生理盐水中的10%贺斯在治疗有严重血浆渗漏的DHF病例时的有效性及其对肾功能、止血、疾病严重程度和并发症的影响。
入住QSNICH登革热病房、对传统晶体溶液无反应的DHF患者被随机分配接受右旋糖酐或贺斯治疗。使用SPSS 14.0 for Windows版记录并分析临床和实验室比较结果。
104例DHF患者纳入本研究;57例被分配到右旋糖酐组,47例被分配到贺斯组。平均年龄为8.6±3.9岁。两组中约一半患者需要一剂胶体溶液,25%的患者需要2剂和3剂(p = 0.138)。右旋糖酐组和贺斯组输注的静脉液体平均量分别为119.4和129.3 ml(p = 0.227)。两种胶体溶液推注剂量后血细胞比容的平均下降幅度分别为7.9%和8.5%(p = 0.381)。每组约80%的患者有休克(p = 0.843)。右旋糖酐组和贺斯组天冬氨酸转氨酶(AST)的平均升高分别为598和822 U(p = 0.548),而丙氨酸转氨酶(ALT)升高分别为182和306 U(p = 0.265)。血尿素氮(BUN)和肌酐在正常范围内,使用胶体溶液后下降。使用两种胶体溶液后第1、2和3天的尿量无差异。两组的凝血指标(凝血酶原时间、活化部分凝血活酶时间和凝血酶时间)无差异。右旋糖酐组和贺斯组有明显出血且需要输血的患者分别为15.8%和19.2%(p = 0.423)。右旋糖酐组和贺斯组液体超负荷的发生率分别为35.1%和40.4%(p = 0.360)。右旋糖酐组和贺斯组的其他并发症无差异,如下:低钙血症、低钠血症、低钾血症和酸中毒。两组患者的总体严重程度和并发症均远高于对传统晶体溶液有反应DHF患者。使用两种胶体溶液后均未发现过敏反应。
10%贺斯在治疗有严重血浆渗漏的DHF患者方面与10%右旋糖酐-40同样有效。两组在DHF疾病严重程度和并发症方面无差异,但观察到疾病严重程度和并发症,尤其是液体超负荷情况与入院的DHF患者更具可比性。两种胶体溶液对DHF患者均安全,未观察到过敏反应,且对肾功能和止血无干扰。